Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma

Creative Commons License

ÜNEK İ. T., Akman T., ÖZTOP İ., Unal O. U., Salman T., Yilmaz U.

GASTRIC CANCER, vol.16, no.3, pp.428-434, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 16 Issue: 3
  • Publication Date: 2013
  • Doi Number: 10.1007/s10120-012-0206-x
  • Journal Name: GASTRIC CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.428-434
  • Keywords: Advanced gastric cancer, Docetaxel, Cisplatin, Leucovorin, 5-Fluorouracil, PHASE-II TRIAL, PROSPECTIVE RANDOMIZED-TRIAL, PROTRACTED VENOUS-INFUSION, QUALITY-OF-LIFE, PLUS CISPLATIN, FOLINIC ACID, GASTROESOPHAGEAL JUNCTION, 1ST-LINE THERAPY, COMBINATION CHEMOTHERAPY, MITOMYCIN-C
  • Dokuz Eylül University Affiliated: Yes

Abstract

The combination of docetaxel, cisplatin, and 5-fluorouracil (DCF) is an effective but highly toxic regimen for the treatment of advanced gastric cancer. To improve tolerability while maintaining the efficacy of the DCF regimen, we developed a modified DCF regimen including an infusional 5-fluorouracil administration according to the de Gramont regimen.